Claritas Pharmaceuticals Inc V.CLAS.H

Changes in Fair Value

[Captainblk]

Changes in Fair-Value The primary factors relating to the Companys net loss in Q3 2019 compared with its net profit in Q3 2018 were several partially offsetting changes in the fair-values of certain contingent liabilities and in-process research and development that were charged to income. These changes in fair-values also resulted in corresponding changes to the Companys balance sheet. Liquidity and Capital Resources At September 30, 2019, the Companys current assets, including cash and cash equivalents and other receivables, increased to approximately $861,000 from approximately $747,000 at December 31, 2018. The Companys current liabilities at September 30, 2019, including accounts payable, current maturities on certain outstanding convertible debentures, and other payables and accrued expenses, decreased to approximately $6M from approximately $7.8M at December 31, 2018